25 July 2017 -- 27 July 2017, 0900 - 1700
The growing disease burden and emergence of innovative new therapeutics means that the multi-billion dollar ophthalmic drug market is poised for near double digit compound growth over the next 5 years. There is enormous untapped potential for companies focusing on developing novel approaches to tackle age related macular degeneration, diabetic macular edema, glaucoma and other degenerative ocular conditions.
Focussing specifically on the challenges drug developers face in the development and delivery of clinically effective ocular drugs, the 2nd Annual Ophthalmic Drug Development Summit is your opportunity to fast-track your development efforts in this space.
Rather than covering early stage research or pipeline overviews, this meeting will unite leaders from Novartis, Genentech, Santen, Astellas and Spark Therapeutics to deliver granular, in-depth insights that will help you accelerate the progress of your ocular drug pipeline.
Academic Earlybird: USD 1299
Academic Standard: USD 1599
Earlybird: USD 2299
Standard: USD 2599
Speakers: Melissa Liew Novartis, Emmett Cunningham Clarus Ventures, Glenn Noronha Clearside Biomedical, T. Michael Nork University of Wisconsin, Ram Palanki Vice President Santen, Jason Ehrlich Genentech